OBJECTIVES/HYPOTHESIS: To determine if tumor biomarkers were predictive of outcome in a prospective cohort of patients with advanced larynx cancer treated in a phase II clinical trial. STUDY DESIGN: Prospectively collected biopsy specimens from 58 patients entered into a Phase II trial of organ preservation in advanced laryngeal cancer were evaluated for expression of a large panel of biomarkers, and correlations with outcome were determined. METHODS: Tissue microarrays were constructed from pretreatment biopsies and stained for cyclin D1, CD24, EGFR, MDM2, PCNA, p53, survivin, Bcl-xL, Bcl-2, BAK, rhoC, and NFκB. Pattern of invasion and p53 mutations were assessed. Correlations with overall survival (OS), disease-specific survival (DSS), time free from indication of surgery, induction chemotherapy response, and chemoradiation response were determined. Cox models were used to assess combinations of these biomarkers. RESULTS: Low expression of BAK was associated with response to induction chemotherapy. Low expression of BAK and cytoplasmic NFκB was associated with chemoradiation response. Aggressive histologic growth pattern was associated with response induction chemotherapy. Expression of cyclin D1 was predictive of overall and disease-specific survival. Overexpression of EGFR was also associated with an increased risk of death from disease. Bcl-xL expression increased significantly in persistent/recurrent tumors specimens when compared to pretreatment specimens derived from the same patient (P = 0.0003). CONCLUSIONS: Evaluation of biomarker expression in pretreatment biopsy specimens can lend important predictive and prognostic information for patients with advanced larynx cancer.
OBJECTIVES/HYPOTHESIS: To determine if tumor biomarkers were predictive of outcome in a prospective cohort of patients with advanced larynx cancer treated in a phase II clinical trial. STUDY DESIGN: Prospectively collected biopsy specimens from 58 patients entered into a Phase II trial of organ preservation in advanced laryngeal cancer were evaluated for expression of a large panel of biomarkers, and correlations with outcome were determined. METHODS: Tissue microarrays were constructed from pretreatment biopsies and stained for cyclin D1, CD24, EGFR, MDM2, PCNA, p53, survivin, Bcl-xL, Bcl-2, BAK, rhoC, and NFκB. Pattern of invasion and p53 mutations were assessed. Correlations with overall survival (OS), disease-specific survival (DSS), time free from indication of surgery, induction chemotherapy response, and chemoradiation response were determined. Cox models were used to assess combinations of these biomarkers. RESULTS: Low expression of BAK was associated with response to induction chemotherapy. Low expression of BAK and cytoplasmic NFκB was associated with chemoradiation response. Aggressive histologic growth pattern was associated with response induction chemotherapy. Expression of cyclin D1 was predictive of overall and disease-specific survival. Overexpression of EGFR was also associated with an increased risk of death from disease. Bcl-xL expression increased significantly in persistent/recurrent tumors specimens when compared to pretreatment specimens derived from the same patient (P = 0.0003). CONCLUSIONS: Evaluation of biomarker expression in pretreatment biopsy specimens can lend important predictive and prognostic information for patients with advanced larynx cancer.
Authors: Andreas Villunger; Ewa M Michalak; Leigh Coultas; Franziska Müllauer; Gunther Böck; Michael J Ausserlechner; Jerry M Adams; Andreas Strasser Journal: Science Date: 2003-09-18 Impact factor: 47.728
Authors: K Kian Ang; Brian A Berkey; Xiaoyu Tu; Hua-Zhong Zhang; Ruth Katz; Elizabeth H Hammond; Karen K Fu; Luka Milas Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Glen Kristiansen; Klaus-Jürgen Winzer; Empar Mayordomo; Joachim Bellach; Karsten Schlüns; Carsten Denkert; Edgar Dahl; Christian Pilarsky; Peter Altevogt; Hans Guski; Manfred Dietel Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Douglas K Trask; Gregory T Wolf; Carol R Bradford; Susan G Fisher; Kenneth Devaney; Mark Johnson; Timothy Singleton; Max Wicha Journal: Laryngoscope Date: 2002-04 Impact factor: 3.325
Authors: Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-04-01 Impact factor: 6.223
Authors: Rebecca Hoesli; Andrew C Birkeland; Andrew J Rosko; Mohamad Issa; Kelsey L Chow; Nicole L Michmerhuizen; Jacqueline E Mann; Steven B Chinn; Andrew G Shuman; Mark E Prince; Gregory T Wolf; Carol R Bradford; Jonathan B McHugh; J Chad Brenner; Matthew E Spector Journal: Oral Oncol Date: 2017-12-23 Impact factor: 5.337
Authors: Andrew J Rosko; Andrew C Birkeland; Kevin F Wilson; Daniel G Muenz; Emily Bellile; Carol R Bradford; Jonathan B McHugh; Matthew E Spector Journal: Otolaryngol Head Neck Surg Date: 2016-03-15 Impact factor: 3.497
Authors: Nghia Nguyen; Emily Bellile; Daffyd Thomas; Jonathan McHugh; Laura Rozek; Shama Virani; Lisa Peterson; Thomas E Carey; Heather Walline; Jeffery Moyer; Matthew Spector; Daniel Perim; Mark Prince; Scott McLean; Carol R Bradford; Jeremy M G Taylor; Gregory T Wolf Journal: Head Neck Date: 2016-02-16 Impact factor: 3.147
Authors: Connor W Hoban; Lauren J Beesley; Emily L Bellile; Yilun Sun; Matthew E Spector; Gregory T Wolf; Jeremy M G Taylor; Andrew G Shuman Journal: Cancer Date: 2017-11-07 Impact factor: 6.860
Authors: Andrew C Birkeland; Megan Yanik; Brittny N Tillman; Megan V Scott; Susan K Foltin; Jacqueline E Mann; Nicole L Michmerhuizen; Megan L Ludwig; Morgan M Sandelski; Christine M Komarck; Thomas E Carey; Mark E P Prince; Carol R Bradford; Jonathan B McHugh; Matthew E Spector; J Chad Brenner Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223